SPN-810 (36 mg)

DRUG2 trials

Sponsors

Supernus Pharmaceuticals, Inc.

Conditions

Attention Deficit Hyperactivity Disorder (ADHD)

Phase 3

Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 2)

CompletedNCT02618434

Supernus Pharmaceuticals, Inc.Attention Deficit Hyperactivity Disorder (ADHD)

Start: 2016-02-16End: 2020-02-14Updated: 2024-03-18

Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 1)

CompletedNCT02618408

Supernus Pharmaceuticals, Inc.Attention Deficit Hyperactivity Disorder (ADHD)

Start: 2016-01-25End: 2019-10-24Updated: 2024-01-02